Over $350 Billion in M&A: Multinational Pharma Giants Rush to Build U.S. Manufacturing Facilities
Johnson & Johnson
Healthcare Product Manufacturers, Health Service Providers
Roche
Oncology Drug Research, Development, and Manufacturing
AstraZeneca
Biopharmaceutical Manufacturer
Eli Lilly
Global Pharmaceutical R&D and Production Company
A rare opportunity, don't miss it!
The Opportunity for Financing Has Arrived!~ Multiple well-known VC firms are seeking high-quality investment targets, Pipelines of interest include: (1) Innovative TCE for solid tumors, (2) Innovative radiopharmaceuticals with new targets/new radionuclides, (3) CNS innovative drugs such as Abeta dual-target, (4) Autoimmune innovative drugs with new targets/new MOA. Biotech companies with relevant products are requested to contact the PharmTimes BD team immediately (BD@drugtimes.cn）！
Main Text:1500Word 1Figure Estimated reading time:6Minute Another MNC demonstrates its "financial prowess" in the United States.
On August 21, 2025, Johnson & Johnson announced once again its significant investment commitment in the United States: over the next decade.Invest $2 Billion in FUJIFILM's New Biopharmaceutical Manufacturing Facility in Holly Springs, North Carolina, to build a dedicated production facility exceeding 160,000 square feet.This investment will not only further expand Johnson & Johnson's advanced drug production capacity in the United States but also bring approximately 120 new job opportunities to North Carolina.
The strategic layout in Holispings is exactly what Johnson & Johnson announced on March 21 this year.A Grand Plan to Invest Over $55 Billion in the U.S. in the Next Four YearsAn important component. This investment increased by 25% compared to the previous four years.
Joaquin Duato, Chairman and CEO of Johnson & Johnson, emphasized that Johnson & Johnson has more production facilities in the United States than in any other country. Through the recently signed One Big Beautiful Bill Act, the company will continue to expand its investment in the U.S. and lead the next era of healthcare innovation. 
Under the "Tariff Stick," MNCs Increase Investment in the U.S.
A rare opportunity, don't miss it!
The Opportunity for Financing Has Arrived!~ Multiple well-known VC firms are seeking high-quality investment targets, Pipelines of interest include: (1) Innovative TCE for solid tumors, (2) Innovative radiopharmaceuticals with new targets/new radionuclides, (3) CNS innovative drugs such as Abeta dual-target, (4) Autoimmune innovative drugs with new targets/new MOA. Biotech companies with relevant products are requested to contact the PharmTimes BD team immediately (BD@drugtimes.cn）！
Main Text:1500Word 1Figure Estimated reading time:6Minute Another MNC demonstrates its "financial prowess" in the United States.
On August 21, 2025, Johnson & Johnson announced once again its significant investment commitment in the United States: over the next decade.Invest $2 Billion in FUJIFILM's New Biopharmaceutical Manufacturing Facility in Holly Springs, North Carolina, to build a dedicated production facility exceeding 160,000 square feet.This investment will not only further expand Johnson & Johnson's advanced drug production capacity in the United States but also bring approximately 120 new job opportunities to North Carolina.
The strategic layout in Holispings is exactly what Johnson & Johnson announced on March 21 this year.A Grand Plan to Invest Over $55 Billion in the U.S. in the Next Four YearsAn important component. This investment increased by 25% compared to the previous four years.
Joaquin Duato, Chairman and CEO of Johnson & Johnson, emphasized that Johnson & Johnson has more production facilities in the United States than in any other country. Through the recently signed One Big Beautiful Bill Act, the company will continue to expand its investment in the U.S. and lead the next era of healthcare innovation. Under the "Tariff Stick," MNCs Increase Investment in the U.S.
A rare opportunity, don't miss it!
The Opportunity for Financing Has Arrived!~ Multiple well-known VC firms are seeking high-quality investment targets, Pipelines of interest include: (1) Innovative TCE for solid tumors, (2) Innovative radiopharmaceuticals with new targets/new radionuclides, (3) CNS innovative drugs such as Abeta dual-target, (4) Autoimmune innovative drugs with new targets/new MOA. Biotech companies with relevant products are requested to contact the PharmTimes BD team immediately (BD@drugtimes.cn）！
A rare opportunity, don't miss it!
The Opportunity for Financing Has Arrived!~ Multiple well-known VC firms are seeking high-quality investment targets, Pipelines of interest include: (1) Innovative TCE for solid tumors, (2) Innovative radiopharmaceuticals with new targets/new radionuclides, (3) CNS innovative drugs such as Abeta dual-target, (4) Autoimmune innovative drugs with new targets/new MOA. Biotech companies with relevant products are requested to contact the PharmTimes BD team immediately (BD@drugtimes.cn）！
A rare opportunity, don't miss it!Under the "Tariff Stick," MNCs Increase Investment in the U.S.
Johnson & Johnson's large-scale investment in the U.S. is not an isolated case. From Eli Lilly to Novartis, from Merck to Gilead,A political storm-driven“Manufacturing Reshoring”Sweeping Across America. And at the center of the storm was that man—Donald.·Trump.
Since the beginning of this year, Trump has repeatedly hinted at imposing tariffs on imported drugs.4The month also launched the drug232Clause Investigation. Under the continuous "tariff stick," MNCs, to avoid potential tariff risks, have increased their investment in the United States, planning to build or expand production bases.
According to incomplete statistics from PharmaTimes,As of now, the total amount of public investments by multinational pharmaceutical companies in the U.S. for 2025 has exceeded 350 billion U.S. dollars.Among themJohnson & Johnson, Roche, and AstraZeneca have the largest investment in the United States, all exceeding500Billion US dollars，Ranked at the forefront.
"American-Style Price Hike for Equality"
Under Trump's erratic policy style,MNCThe drug pricing and layout strategy has added a lot of uncertainty.
2025Year8Month1In the early hours of the day, Trump on his social platformTruth SocialOnce again staged“Twitter Storm”, shortly6Furious in Minutes17A tweet, the content of which is written for17An open letter to multinational pharmaceutical companies, requiring these leading pharmaceutical companies to60Execute the "Most Favored Nation" policy within days,Attempt to reduce the reimbursement prices of some Medicare drugs by comparing them with prices in other countries.This may indirectly drive global drug prices to align with those in the U.S., which can be considered a“Price Increase for Equal Rights with American Characteristics”。
Eli Lilly responded quickly, on8Month14Released a statement on the day: is conducting consultations with some national governments, related price adjustments will be made9Month1Recently completed, while ensuring that patients' access to medications remains unaffected. Among these, the agreement reached with the UK government has drawn particular attention: in the UK region,The highest dose ofMounjaro(Tirzepatide Glycemic Control Version) The monthly price will start from122Pound Sterling Rises to330Pound sterling, with gains as high as170%; The price increase for low-dose products is45%To138%Between. Eli Lilly explained to the Financial Times that the purpose of this price adjustment is to“Addressing price differences compared to other developed countries (including European nations)。
And the impact on the UK pharmaceuticals market does not stop there. Additional investment in the US500AstraZeneca, a UK-based company worth billions of dollars, stated: Due to dissatisfaction with the increasingly severe business and investment environment in the UK, AstraZeneca made the decision this year.Cancellation of Investment in Vaccine Manufacturing Plant in Northern England4.5Billion-pound Plan. Even, AstraZenecaCEO Pascal SoriotThrough The Times,Bloomberg...and other overseas media outlets revealed,The company is considering delisting from the London Stock Exchange and moving to the U.S. for listing., in order to seek a more stable and incentive-driven capital market environment.
Conclusion
Trump's Aggressive Use of "Tariffs" Is Reshaping the Fundamental Logic of the Global Pharmaceutical Industry:Innovation no longer belongs only to the laboratory; it also emerges from the meeting rooms of policy negotiations.Corporate strategic decisions are no longer driven solely by science and the market but are increasingly swayed by a president's social dynamics.
This "Reshoring of Manufacturing" seems bustling on the surface, but beneath lies a surge of hidden challenges. In the short term, companies are using their "cash power" to secure policy safety; in the long run, however, it faces the risk of a forced restructuring of the global supply chain and the collapse and rebuilding of the drug pricing system. As "America First" evolves into "global price hikes for equity," the ones footing the bill may not only be the healthcare insurance systems but also the cornerstone of global patients' trust in the pharmaceutical industry. Whether this "Great Pharmaceutical Migration," ignited by politics, will drive innovation or exacerbate division, only time will tell. PharmaTimes will continue to monitor the situation.
3.Eli Lilly: Tirzepatide Price Increase of 170% in the UK(Official Account: PharmaTimes)
4. MNC "Rush to the Shore" Intensifies! Gilead, Takeda, and Others Pave the Way with Billions, Over 10 Giants Enter the Fray...Official Account:Yidu Medicine
5. Eli Lilly, Johnson & Johnson and More Than a Dozen Other Pharmaceutical Giants Announce Factory Construction in the U.S., with a Total Investment of Over 2 Trillion Yuan! Enough to Build 640 Bird's Nest Stadiums(WeChat Official Account: Dingxiangyuan Insight Database)）
6. Other Public Information
2025-08-22
2025-08-21
2025-08-21
Copyright Statement/Disclaimer
This article is an original piece.
This article is for information exchange purposes only and does not provide any commercial, medical, or investment advice.
The images, videos, fonts, music, and other materials in the article are either authorized genuine works purchased by PharmaTimes, sourced from the WeChat public image library, taken from the company's official website or the Internet, or used under the CC0 protocol. All copyrights belong to the respective owners, and PharmaTimes makes every effort to acknowledge the sources.
If you have any questions, please contact us.
Sincerely grateful!
DrugTimes Official Website: www.drugtimes.cn
Contact Information:
Phone: 13651980212
WeChat: 27674131
Email: contact@drugtimes.cn
Click here to view more highlights!